0
0
6/10/23 at 1:00am
Organization
The Washington Post
Author
Laurie McGinley
33 words
0
Comments
Controversies surrounding the drug — involving safety concerns, the drug’s modest efficacy and its high cost — continue to swirl.
You are the first to view
https://www.washingtonpost.com/health/2023/06/09/alzheimers-drug-leqembi-fda/
Create an account
or login to join the discussion